Formycon AG
FYB
Company Profile
Business description
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID-19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Contact
Fraunhoferstrasse 15
Martinsried
PlaneggBY82152
DEUT: +49 89864667100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
235
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,939.70 | 378.00 | 5.00% |
| CAC 40 | 6,896.91 | 203.51 | -2.87% |
| DAX 40 | 19,670.88 | 609.38 | -3.00% |
| Dow JONES (US) | 40,608.45 | 62.52 | 0.15% |
| FTSE 100 | 7,705.87 | 204.66 | -2.59% |
| HKSE | 20,264.49 | 136.81 | 0.68% |
| NASDAQ | 17,124.97 | 574.37 | 3.47% |
| Nikkei 225 | 34,269.71 | 2,555.68 | 8.06% |
| NZX 50 Index | 12,232.46 | 425.91 | 3.61% |
| S&P 500 | 5,456.90 | 474.13 | 9.52% |
| S&P/ASX 200 | 7,742.40 | 367.40 | 4.98% |
| SSE Composite Index | 3,186.81 | 0.00 | 0.00% |